Mind Cure Health (CSE: MCUR) is the latest issuer to become involved in operating psychedelic-assisted mental health therapy clinics. The company this morning announced that it intends to open its first health centre in Kelowna, British Columbia, with the centre being used for the training of therapists as well as to offer mental health therapy that is assisted through the use of ketamine and psilocybin under Section 56 under Canadian drug laws.

The Mind Cure Health Centre is said to enable the treatment and study of psychedelic-assisted therapy, while enabling the company to provide “personalized and technology enabled care.” Through the use of technology, the company will be able to provide support before, during, and after treatment.

The Centre itself will consist of eight treatment rooms for its psychedelic therapy, while also serving the role of a training hub, with a scheduled opening date of May 2021. The company intends to offer a training program for therapists, enabling them to provide psychedelic-assisted therapy at their own clinics. For those that prefer not to offer it at their own clinics, it will enable the therapists to become comfortable with referring their own clients for Mind Cure’s services.

“We have always seen our business as caring for individual mental health and wellness on a spectrum, from those who are suffering and are in need of relief to those who are looking for enhanced clarity, focus and overall well-being. [..] Kelowna is a logical first location for a Mind Cure Health Center, both because of its proximity to Vancouver and Calgary, International Airports, as well as its growing local population and reputation as a destination city.”

Kelsey Ramsden, President and CEO of Mind Cure Health

The announcement of the Mind Cure Health Centre follows the news earlier this week that the company is in the process of beginning a translational research program. That program, which is focused on improving health outcomes in patients through the use of psychedelic compounds, will first be implemented at the Mind Cure Health Centre, with the initial focus being on that of psilocybin and ketamine.

Mind Cure Health last traded at $0.67 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

The post Mind Cure To Launch Psychedelic Assisted Mental Health Therapy Centre appeared first on the deep dive.